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The frequency and risk factors of developing lymphedema 
of the upper extremity after breast conserving therapy
Anna Niwiƒska1, Hanna Tchórzewska2, Ma∏gorzata Procner2, Ewa Kraszewska3
A i m.  The aim of the study was to evaluate the frequency of lymphedema of the upper extremity in breast cancer patients after
breast conserving therapy (BCT) and to assess the risk factors influencing this complication.
M a t e r i a l  a n d  m e t h o d s.  We evaluated 174 patients with breast cancer, mean age 53 yrs, stage 0, I and II undergoing BCT
at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw between the years1995 and
1999. Mean follow-up time was 50 months. Adjuvant chemotherapy or hormonotharpy had been administered to 83 pts. The
cicumference of both arms was measured by tape 10 cm above the lateral epicondyle, 10 cm below it and at the metacarpal
level. A difference of 2-4 cm was recognized as mild; of 4-6 cm as moderate and over 6 cm as severe lymphedema. In order to
assess the risk factors of lymphedema we performed a statistical analysis of the following elements: age, tumour location,
number of excised nodes, number of metastatic lymph nodes, radiotherapy to lymph node areas and adjuvant systemic
therapy.
R e s u l t s.  We observed 17/174 (10%) cases of lymphedema – 15/17 mild; 1/17 moderate and 1/17 severe. On statistical
analysis we found, that the only factor affecting lymphedema was irradiation to the lymph node areas.
C o n c l u s i o n.  The incidence of lymphedema of the upper extremity after breast conserving therapy is low (10%), similar to
published data. Radiotherapy of the lymph node areas is the only factor increasing the risk of lymphedema.
Ocena cz´stoÊci wyst´powania i czynników ryzyka obrz´ku  limfatycznego koƒczyny górnej 
u  chorych  na  raka  piersi  po leczeniu  oszcz´dzajàcym
C e l. Celem pracy by∏a ocena cz´stoÊci wyst´powania i stopnia nasilenia obrz´ku limfatycznego koƒczyny górnej u chorych na
raka piersi po leczeniu oszcz´dzajàcym oraz analiza czynników ryzyka wystàpienia obrz´ku.
M a t e r i a ∏  i m e t o d a. Poddano analizie 174 chore na raka piersi w stopniu zaawansowania klinicznego 0, I i II, leczonych
w Centrum Onkologii w Warszawie w latach 1995-1999. Âredni czas obserwacji wynosi∏ 50 miesi´cy. U wszystkich chorych wy-
konano tumorektomi´ lub kwadrantektomi´ z limfangiektomià pachowà oraz napromienianie na pierÊ. U 83 chorych prze-
prowadzono chemioterapi´ lub hormonoterapi´ uzupe∏niajàcà. W trakcie leczenia pierwotnego wszystkie chore odby∏y instruk-
ta˝ w Zak∏adzie Rehabilitacji, dotyczàcy profilaktyki przeciwobrz´kowej. Po Êrednim czasie obserwacji 50 miesi´cy wykona-
no pomiary obwodów koƒczyny górnej po stronie leczonej i porównano je z obwodami po stronie zdrowej. Pomiary
przeprowadzono na wysokoÊci ramienia, przedramienia i Êródr´cza. Obrz´k uznano za niewielki, jeÊli ró˝nica pomiarów wy-
nosi∏a 2-4 cm, Êredni – 4-6 cm i du˝y >6 cm. Poddano analizie wielowariantowej regresji logitowej nast´pujàce czynniki, mo-
gàce mieç wp∏yw na wystàpienie obrz´ku: wiek, lokalizacj´ raka w piersi, stopieƒ zaawansowania, liczb´ usuni´tych w´z∏ów
ch∏onnych, liczb´ zmienionych przerzutowo w´z∏ów ch∏onnych, napromienianie okolic w´z∏owych, chemioterapi´ i hormono-
terapi´ uzupe∏niajàcà.
W y n i k i. Obrz´k koƒczyny stwierdzono u 17 chorych (10%). U 15 z nich (88%) obrz´k by∏ niewielki, u 1- Êrednio
zaawansowany, u 1 – du˝y. Na podstawie analizy wieloczynnikowej wykazano, ˝e jedynie napromienianie okolic w´z∏owych
w sposób statystycznie znamienny zwi´ksza∏o ryzyko wystàpienia obrz´ku.
W n i o s k i.  Obrz´k koƒczyny górnej u chorych po leczeniu oszcz´dzajàcym, przeprowadzanym w Centrum Onkologii
w Warszawie, wyst´puje rzadko i nie stanowi istotnego problemu klinicznego. Zadowalajàce wyniki mogà mieç zwiàzek
z rutynowym stosowaniem w Centrum Onkologii w Warszawie profilaktyki przeciwobrz´kowej. Wyniki sà porównywalne
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Introduction
Lymphedema is the most common complication observed
in patients treated for breast cancer. It is caused by the
narrowing or destruction of lymphatic vessels, which may
occur in the course of surgery, radiotherapy, infections
and/or phlebitis.
One may discern acute and chronic lymphedema [1,
2]. The acute form is transient in character, appears
during the first six weeks after surgery, lasts for some 3 to
6 months and usually disappears without treatment. The
chronic form appears at some point between 6 months
and many years after surgery and takes on the form of
permanent cutaneous changes. The severity of lymphe-
dema is divided into three grades – in grade 1 (the acute
phase) edema disappears when the extremity is elevated;
in grade II (the onset of the chronic phase) edema
appears due to changes in the albumin/globulin ratio in
the subcutaneous tissue, which in turn causes an increase
in interstitial pressure and connective tissue proliferation.
In grade III (the chronic phase), often referred to as
elephantiasis, one observes massive edema and hardening
of the extremity.
The percentage of patients with lymphedema varies
in different literature reports – from 6.7% to 89% [1, 3-
12]. Such discrepancies may arise from a variety of
surgical modalities, from different combinations of
surgery and radiotherapy and may also depend on the
time gap after which the measurements were performed,
counting from the termination of treatment [2]. An
analysis of 1650 patients treated at the Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology
in Warsaw between the years 1950 and 1970 has revealed
that lymphedema was observed in 21.6% of patients after
the Patey procedure, in 43.2% of patients after the
Halstedt procedure and in 42.4% after Urban procedure.
After perioperative irradiation this ratio increased to
30.8%, 62.1% and 57.5%, respectively [4]. American
authors publishing over that very time period report from
6.7% to 62.5% of cases with lymphedema [5], while
British – between 41% and 70%.
After BCT lymphedema is observed in 10% of
patients on average – varying between 2% and 24% and
depending upon the extent of surgery, irradaiation and
the observation period [6-9, 11]. There exist no Polish
literature reports concerning the frequency of lymphe-
dema after BCT.
Aim
The aim of this study was to evaluate the frequency and
the degree of lymphedema in breast cancer patients after
BCT and to analyse the factors which may affect the
development of this complication.
Material and method
174 breast cancer patients, median age 53 years (range: 28-76
yrs) were treated according to the BCT protocol at the Maria
Sklodowska-Curie Memorial Cancer Center and Institute of
Oncology in Warsaw between the years1995 and 1999. Follow-up
ranged between 24 and 78 months; median 50 yrs. The first
stage of treatment was tumorectomy (quadrantectomy) with
axillary lymphadenectomy; then the breast was irradiated
conventionally; i.e. 4-6 MeV of photons or Co-60 from two
tangential fields up to a total dose of 50 Gy in 25 fractions (2 Gy
per fraction). Patients with invasive carcinoma received an
additional boost to the tumour site of with an individually
calculated electron beam or from Ir192 implantation. A majority
of patients received adjuvant treatment – either chemotherapy or
tamoxifen. Patients treated according to the CMF protocol
(cyclophosphamide, methotrexate, fluorouracil) were irradiated
during chemotherapy, while patients treated according to
anthracycline containing regimens were irradiated after the
completion of chemotherapy. The characteristics of patient
material are presented in Table I.
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z danymi z piÊmiennictwa. Radioterapia uzupe∏niajàca okolic w´z∏owych (zw∏aszcza okolicy pachy) ponad 4-krotnie zwi´ksza
ryzyko wystàpienia obrz´ku. 
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Table I. Patient characteristics
No. of patients 174
Age in yrs. 28-76 mean 52
Follow-up duration in mos. 24-78
Mean 50
Median 50
Grade of clinical advancement T0N0M0- T2N1M0
0 17
I 132
II a 21
II b 4
Tumour localisation:
Upper external quadrant or Spence’s tail 122
Other 52
Type of operation:
Quadrantectomy and lymphadenectomy 13
Tumorectomy and lymphadenectomy 150
Tumorectomy 11
Radiotherapy:
Breast only 164
Breast and nodal fields 10
Chemotherapy:
Yes 47
No 127
Hormonotherapy:
Yes 36
No 138
In the course of treatment all patients completed a course
of rehabilitation training at the Dept. of Rehabilitation of the
Maria Sklodowska-Curie Memorial Cancer Center.
Circumference measurements were compared on both
extremities 10 cm above the lateral epicondyle, 10 cm below it
and at the metacarpal level. Edema was recognized if the
difference between the circumference was equal to or greater
than 2 cm at least at one measurement level.
S t a t i s t i c a l  m e t h o d s
Patient characteristics were presented using standard methods –
mean value and standard deviation and frequency tables. The
influence of the different clinical factors (patient age, tumour
localization, TNM advancement, number of excised nodes,
number of metastatic nodes, irradiation of nodal areas, chemo-
therapy and radiotherapy) on the frequency of lymphedema of
the upper extremity was analysed according to a multivariate
model of logit regression. Stepwise elimination allowed us to
identify statistically significant factors at a level of 0.05.
Results
We observed 10% of cases of lymphedema (17/172) in
patients after BCT. A majority of these – 88% (15/17)
were pronounced as grade I. In 12/17 pts (70%) edema
was discernible only on one measurement level. Results
are presented in Table II.
We performed an analysis of the factors which could
affect the development of lymphedema – age (under 50 vs
over 50 yrs.); tumour localization (upper external qua-
drant and Spence’s tail vs all other); TNM advancement;
number of excised nodes (10 vs more than 10), nodal
metastases, irradiation of lymph node fields, chemo-
therapy and hormonotherapy. Multivariate analysis has
revealed that the only factor which achieved statistical
significance in its influence on the frequency of lymphe-
dema was irradiation of the nodal fields after lymphade-
nectomy. Patients who were irradiated to the nodal fields
had a 4.6 higher risk of developing lymphedema than
patients without nodal field irradiation (chance quotient
4.62, confidence interval 1.07 to 19.88; p = 0.040). Patient
characteristics as regarding the distribution of risk factors
are presented Table III, while the results of the logit
analysis are presented in Table IV.
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Table III. An analysis of the factors affecting the development of lymphedema of the upper extremity 
in breast cancer patients after BCT
Factor Pts without lymphedema Pts with lymphedema
(n = 157) (n =17)
Age:
50 yrs. ad less 82 / 157 (52%) 9 / 17 (53%)
51 yrs.and over 75 / 175 8 / 17
Quadrant of the breast:
Upper external and Spence’s tail 110 / 157 (70%) 12 / 17 (70%)
Other 47 / 157 5 / 17
No. of excised lymph nodes:
Mean 15 16
Median 15 15
Nodal metastases on histopathological examination:
Yes 29 / 157 (18%) 5 / 17 (29%)
No 128 / 157 12 / 17
Hormonotherapy:
Yes 30 / 157 (19%) 3 / 17 (18%)
No 127 / 157 13 / 17
Chemotherapy:
Yes 43 / 157 (28%) 4 / 17 (24%)
No 114 / 157 13 / 17
Nodal irradiation:
Yes 7 / 157 (5%) 3 / 17 (18%)
No 150 / 157 14 / 17
Table II. The number of patients with lymphedema 
of the upper extremity – including the grade of the edema 
(acc. to the criteria applied at the Dept. of Rehabilitation 
of the Maria Sklodowska-Curie Memorial Cancer Center 
and Institute of Oncology in Warsaw)
Total number of patients with lymphedema 17 / 174 – 10%
Grade of edema
I (2-4 cm difference in circumference) 15 (88%)
II (4-6 cm difference in circumference) 1
III (>6 cm difference in circumference) 1
Edema in 1 measurement 12 (70%)
Edema in 2 measurements 4
Edema in 3 measurements 1
Discussion
M e t h o d s  a p p l i e d  f o r  t h e  m e a s u r e m e n t  o f
l y m p h e d e m a
Measurements of lymphedema of the upper extremity
may be performed according to three different methods.
The first method is limited to the comparison of the
circumferences measured at different levels on both
extremities. The second method involves the measure-
ment if the volume of the extremities basing upon their
immersion in measurement vessels filled with water. The
third method bases upon the evaluation of the tonus of
the skin and the subcutaneous tissue – i.e. the measu-
rement of bioelectric resistance in the affected extremity
[11, 13]. The Dept.of Rehabilitation of the Maria Sklo-
dowska-Curie Memorial Cancer Center and Institute of
Oncology applies the first of these methods, with
measurements taken with measuring tape at three points
– 10 cm above the lateral epicondyle, 10 cm below it and
at the metacarpal level, excluding the thumb. The diffe-
rence between the extremities is then calculated at each
level.
The consistency of the eedematous tissue is
evaluated at different points and referred to as “soft”
edema and “hard” edema. Three grades of edema are
recognized – a difference in circumference of 2-4 cm is
recognized as mild edema; of 4-6 cm as – moderate and
over 6 cm – as severe lymphedema [14]. Some authors
accept different criteria; acc. to which a difference in
circumference of up to 3 cm is recognized as mild edema;
of 3-5 cm as moderate and over 5 cm – as severe
lymphedema, with differences in volume reported as 150-
400 ml; 400-700 ml and over 750 ml, respectively [2].
When applying these critreria one must make a certain
allowance for the dominant extremity which, usually, has
a larger diameter.
P r e v e n t i o n  a n d  t r e a t m e n t
Due to the fact that the treatment of lymphedema is long-
lasting and, in more advanced cases, achieves relatively
poor results, its prevention becomes an important issue.
The basic element of prophylaxis is automassage and
elements of Vooder massage (lymphatic drainage) [15].
The patients are advised to take the following preventive
measures: elevate the affected extremity during sleep and
when resting, avoid blood pressure measurements and
all kinds of injections on the affected extremity, refrain
from more extreme physical exercise, avoid tight sleeves
or watch straps and avoid excessive heat (hot baths,
balms) and lesions (cuts, burns, insect bites etc) on the
affected extremity. Every-day physical exercise adequately
chosen in view of the patient’s possibilities is also an
important preventive measure, as it allows to maintain
complete movement in the joints and provides lymphatic
drainage and circulation thanks to the muscle pump.
Kinetotherapy (movement exercises) is also a good
method for the complex treatment of lymphedema, as
well as various forms of massage which increase lymphatic
circulation: lymphatic drainage, specialistic compression
sleeves which adapt to the grade of edema (elastic
sleeves), underwater whirl massage and pulsating pneu-
matic pressure. Surgical treatment is not very effective; its
principle lie in either creating anastomoses of the
lymphatic vessels into veins or on the liposuction of the
edematous fatty tissue from the affected extremity [11].
Pharmacological treatment is ineffective – among the
different drugs used the most popular are diuretics,
flavonoids and cumarin derivatives [11].
Fr e q u e n c y
The frequency of the development of lymphedema in
patients with breast cancer has significantly diminished
over the last few years. This probably arises from the
growing popularity of less extensive surgical methods and
from the fact that breast cancer is now often diagnosed at
an earlier stage. In patients treated with BCT the risk of
lymphedema varies between 2% and 24%, approx. 10%
on average [6-9, 11, 16]. According to Larson et al. 6
years after the completion of treatment in patients who
had undergone BCT without axillary lymphadenectomy
the risk of lymphedema is 4%; after dissection of the
inferior level – only 7%, and after dissection of the three
levels of axillary lymph nodes – 13%; while after
dissection of the three levels of axillary lymph nodes and
irradiation of the nodal fields this increases to 36% [10].
In the paper of Meric et al. the frequency of lymphedema
observed 7 yrs. from treatment completion was 10% after
axillary lymphadenectomy and 18% after axillary lympha-
denectomy and irradiation [17]. Kwan et al. have estima-
ted the frequency of lymphedema at 12% in a group of
744 pts. after BCT. The probability of developing lymphe-
dema increased in patients who had undergone axillary
lymphadenectomy with irradiation [18]. Voogdt et al.
have evaluated a group of 465 pts, finding 2 cm
differences in diameter in 26% of patients [19], while
Beaulac et al. have analysed 151 patients after BCT or
mastectomy without irradiation and estimated the risk
of lymphedema at 27.8% [20].
In our material we observed lymphedema in 10%
of patients. This is a satisfactory result when compared
with literature data, all the more in view of the fact that all
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Table IV. The results of multivariate analysis – logit regression model
Risk factor of lymphedema Chance quotient Standard deviation P Confidence interval 95%
Radiotherapy of nodal fields 4.62 3.44 0.040 1.07- 19.89
patients underwent lymphadenectomy of all the three
levels of axillary lymph nodes. It is also necessary to stress
that in a vast majority of patients (70%) we observed
differences in the diameter of the extremities only at one
level, while in 88% of these patients the difference was
between 2 and 4 cm. We believe that such good results
arise from the fact that all BCT patients had completed
a course in lymphedema prevention at the Dept. of
Rehabilitation of the Maria Sklodowska-Curie Memorial
Cancer Center and Institute of Oncology in Warsaw.
R i s k  f a c t o r s
The risk factors responsible for the development of
lymphedema may be divided into three groups. The first
group consists of treatment-related risk factors, especially
in the case of combined treatment modalities: surgery,
systemic therapy and irradiation. The extent of surgery is
an important element – especially within the axilla. There
exists a linear relationship between the number of excised
nodes (lower level vs two levels vs three levels of axillary
nodes) and the probability of developing lymphedema
[1, 11]. The frequency of lymphedema reaches 2-27%, at
an average of 10% [16]. Irradiation of the axillary fossa
after dissection of the three levels of the axillary nodes
increases this risk to 12-30% [1, 12, 16, 21, 22]. Isolated
irradiation of the axillary fossa without lymphadenectomy
carries a 2-5% risk of lymphedema, although it appears at
a later stage than in the case of isolated surgery or
combined surgery and irradiation [16]. The second group
of risk factors combines disease-related issues –
advancement, the number of involved lymph nodes and
the location of the tumour within the breast. The
probability of developing lymphedema increases with the
size of the primary tumour and the number of involved
nodes [1, 2, 12]. The third group consists of patient-
related risk factors – age [23], obesity [6], arterial
hypertension, phlebitis, over-exercising the affected
extremity, appearance of early lymphedema after surgery
and the time laps since treatment completion [2, 11, 23].
The risk of developing lymphedema increases with the
age of the patient [23], although this is not confirmed by
all authors [6].
It is a common belief that of all these risk factors
the most significant one is extensive surgery (especially
involving the dissection of all three levels of axillary lymph
nodes) combined with irradiation of the lymph node areas
[16].
In our material the extent of surgery was comparable
– tumorectomy and lymph node dissection of all the three
levels of the axillary nodes. In the case of 10 patients
irradiation involved not only the breast, but also the nodal
areas and in the case of these patients there was a 4.6
times greater risk of developing lymphedema. Radio-
therapy to the nodal fields was one of the seven analysed
factors, which significantly increased the risk of lymphe-
dema of the upper extremity. We did not confirm the
influence of patient age, tumour size, tumour localization
within the breast, the number of excised lymph nodes
and the number of metastatic nodes, chemotherapy nor
hormonotherapy on the risk of developing lymphedema.
Conclusions
1. In the case of breast cancer patients treated with
conserving therapy at the Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology
in Warsaw the risk of developing lymphedema of the
upper extremity is estimated at 10%. In a majority of
cases (88%) the extent of lymphedema is mild.
2. The most important risk factor affecting the deve-
lopment of lymphedema after breast conserving
therapy in this patient group is irradiation of the nodal
fields.
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